2-bromo-α-(4-chlorophenyl)-5-methoxybenzenemethanol | 1173238-24-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-α-(4-chlorophenyl)-5-methoxybenzenemethanol
• 英文别名: (2-bromo-5-methoxyphenyl)(4-chlorophenyl)methanol；(2-Bromo-5-methoxyphenyl)-(4-chlorophenyl)methanol；(2-bromo-5-methoxyphenyl)-(4-chlorophenyl)methanol
• CAS: 1173238-24-8
• 化学式: C₁₄H₁₂BrClO₂
• 分子量: 327.605
• InChiKey: KXCMDNYYHIHDJK-UHFFFAOYSA-N

物化性质

• 沸点：
  441.5±45.0 °C(Predicted)
• 密度：
  1.494±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  18
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-α-(4-chlorophenyl)-5-methoxybenzenemethanol 在 4-二甲氨基吡啶 、 (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride 、 四(三苯基膦)钯 、 甲酸铵 、 potassium acetate 、 sodium carbonate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 pyridinium chlorochromate 、 sodium hydroxide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 水 为溶剂， 反应 44.0h， 生成 2-(6-(4-chlorophenyl)-8-methoxy-1-methyl-2-oxo-1,4-dihydro-2H-benzo[c]thiazolo[4,5-e]azepin-4-yl)-N-ethylacetamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of novel 6-phenyl-1,3a,4,10b-tetrahydro-2H-benzo[c]thiazolo[4,5-e]azepin-2-one derivatives as potential BRD4 inhibitors

  摘要：

  Bromodomain-containing protein 4 (BRD4) is a key epigenetic regulator in cancer, and inhibitors targeting BRD4 exhibit great anticancer activity. By replacing the methyltriazole ring of the BRD4 inhibitor I-BET-762 with an N-methylthiazolidone heterocyclic ring, fifteen novel BRD4 inhibitors were designed and synthesized. Compound 13f had a hydrophobic acetylcyclopentanyl side chain, showing the most potent BRD4 inhibitory activity in the BRD4-BD1 inhibition assay (IC50, value of 110 nM), it also significantly suppressed the proliferation of MV-4-11 cells with high BRD4 level (IC50, value of 0.42 mu M). Furthermore, the potent apoptosis-promoting and G0/G1 cycle-arresting activity of compound 13f were indicated by flow cytometry. As the downstream-protein of BRD4, c-Myc was in significantly low expression by compound 13f treatment in a dose-dependent manner. All the findings supported that this novel compound 13f provided a perspective for developing effective BRD4 inhibitors.

  DOI：

  10.1016/j.bmc.2020.115601
• 作为产物：
  描述：

  3-甲氧基苯甲醛 在 溴 、 magnesium 作用下， 以 乙醚 、 溶剂黄146 为溶剂， 反应 5.5h， 生成 2-bromo-α-(4-chlorophenyl)-5-methoxybenzenemethanol
  参考文献：
  名称：

  一种新型的供体-π-受体蒽单体：向更快，更温和的可逆二聚化方向发展

  摘要：

  由容易获得的化合物合成了带有长烷基间隔基和可聚合端基的新颖的2，6-取代的供体-受体蒽衍生物。与蒽和其他报道的蒽衍生物相比，该单体具有共轭电子给体和受体部分，可在更高的波长和更温和的条件下实现紫外线吸收和蒽二聚。与大多数9-取代的蒽相比，该化合物在更高的波长处吸收并二聚更快。研究了二聚体的快速光化学断裂和相对较慢的热断裂，并且与化学结构即2,6-取代有关。

  DOI：

  10.1016/j.tet.2019.01.007

文献信息

• TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER
  申请人：JUBILANT BIOSYS LIMITED

  公开号：US20180282345A1

  公开（公告）日：2018-10-04

  The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.

  本公开描述了Formula I的杂环化合物，其立体异构体，药学上可接受的盐，络合物，水合物，溶剂化合物，互变异构体，多晶型，拉克米混合物，光学活性形式以及其药学活性衍生物，并且含有它们作为活性成分的药物组合物。本公开还描述了合成和表征上述化合物以展示高抗癌活性。本公开的化合物可用作药物，并且可用于制造用于治疗、预防或抑制由一个或多个BET家族溴结构域介导的疾病和病况的药物。
• Tricyclic fused derivatives of 1-(cyclo)alkyl pyridin-2-one useful for the treatment of cancer
  申请人：JUBILANT BIOSYS LIMITED

  公开号：US10689390B2

  公开（公告）日：2020-06-23

  The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.

  本公开描述了式 I 的杂环化合物或其立体异构体、药学上可接受的盐、络合物、水合物、溶 液物、同系物、多晶型物、外消旋混合物、光学活性形式及其药学活性衍生物，以及含有它们作 为活性成分的药物组合物。本公开还介绍了上述化合物的合成和表征方法，这些化合物具有很高的抗癌活性。本公开的化合物可用作药物，并可用于制造治疗、预防或抑制由一种或多种 BET 家族溴化多聚酶介导的疾病和病症的药物。
• Tricyclic fused derivatives of 1-(cyclo)alkyl pyrtdin-2-one useful for the treatment of cancer
  申请人：JUBILANT BIOSYS LIMITED

  公开号：US11319326B2

  公开（公告）日：2022-05-03

  The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.

  本公开描述了式 I 的杂环化合物或其立体异构体、药学上可接受的盐、络合物、水合物、溶 液物、同系物、多晶型物、外消旋混合物、光学活性形式及其药学活性衍生物，以及含有它们作 为活性成分的药物组合物。本公开还介绍了上述化合物的合成和表征方法，这些化合物具有很高的抗癌活性。本公开的化合物可用作药物，并可用于制造治疗、预防或抑制由一种或多种 BET 家族溴化多聚酶介导的疾病和病症的药物。
• Synthesis of 2-Benzothiophene-1(3H)-thione and Isothiochromene-1-thione Derivatives by Iodine-Mediated Cyclization of Lithium 2-(Vinyl)dithiobenzoate Derivatives
  作者：Kazuhiro Kobayashi、Shuhei Fukamachi、Hisatoshi Konishi

  DOI：10.3987/com-08-11514

  日期：——
• [EN] TRICYCLIC FUSED DERIVATIVES OF 1-(CYCLO)ALKYL PYRIDIN-2-ONE USEFUL FOR THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS TRICYCLIQUES CONDENSÉS DE 1-(CYCLO)ALKYL-PYRIDIN-2-ONE UTILES DANS LE TRAITEMENT DU CANCER
  申请人：JUBILANT BIOSYS LTD

  公开号：WO2016157221A1

  公开（公告）日：2016-10-06

  The present disclosure described heterocyclic compounds of Formula I or, its stereoisomers, pharmaceutically acceptable salts, complexes, hydrates, solvates, tautomers, polymorphs, racemic mixtures, optically active forms and pharmaceutically active derivative thereof and pharmaceutical compositions containing them as the active ingredient. The present disclosure also describes the synthesis and characterization of aforementioned compounds to exhibit high anticancer activity. The compounds of the present disclosure are useful as medicaments and their use in the manufacture of medicaments for treatment, prevention or suppression of diseases, and conditions mediated by one or more BET family of bromodomains.